After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia

Table 2

Correlation between dBMA Tregs and AML-related prognostic factors.

	dBMA Tregs
	≤14/μL	>14/μL
	Age			ns^a
Years, median value	55	56
Range	(32-65)	(19-65)
WBC			ns^a
WBC/μl, median value	12500	18400
Range	(1900-281000)	(1400-138000)
Molecular/cytogenetic group^@, %			ns^b
Poor	6 (30)	4 (21)
Intermediate	13 (65)	13 (68)
Good	1 (5)	2 (11)
NPM/FLT3 ,%
NPM1^mut	2 (10)	6 (32)	ns^c
NPM1^wt	18 (90)	13 (68)
FLT3 ITD+ or D835+	6 (30)	3 (16)	ns^c
FLT3^wt	14 (70)	16 (84)
De novo AML, %			ns^c
Yes	17 (85)	16 (84)
No	3 (15)	3 (16)

^@according to ELN 2010 [ITD allelic ratio not performed]. WBC: white blood cells; dBMA Tregs: diagnostic bone marrow aspirate T regulatory cells. AML: acute myeloid leukemia; ^aMann–Whitney rank sum test, ^bchi-square test, ^cFisher’s exact test; ns: not statistically significant.